Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_4
3
50%
Ph not_applicable
1
17%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (20.0%)
Phase 43 (60.0%)
N/A1 (20.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_4

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

NCT02703636
completednot_applicable

Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

NCT01380288
completed

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

NCT01312363
completedphase_4

Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.

NCT02413554
completedphase_4

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

NCT00835159
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02703636Phase 4

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Completed
NCT01380288Not Applicable

Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

Completed
NCT01312363

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

Completed
NCT02413554Phase 4

Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.

Completed
NCT00835159Phase 4

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

Completed
NCT01399125Phase 3

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6